PMID- 35608754
OWN - NLM
STAT- MEDLINE
DCOM- 20220630
LR  - 20221213
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 39
IP  - 7
DP  - 2022 Jul
TI  - Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in 
      Patients with Chronic Lymphocytic Leukemia by Risk Status.
PG  - 3292-3307
LID - 10.1007/s12325-021-01991-5 [doi]
AB  - INTRODUCTION: Certain genetic features in chronic lymphocytic leukemia (CLL) are 
      associated with inferior outcomes after chemoimmunotherapy (CIT). This 
      retrospective study evaluated treatment patterns and clinical outcomes of 
      patients with CLL, stratified into high-risk and non-high-risk groups, who 
      received first-line ibrutinib or CIT therapy. METHODS: High-risk group included 
      confirmed presence of del(17p), del(11q), unmutated IGHV, TP53 mutations, or 
      complex karyotype. Weighted high-risk ibrutinib and CIT groups were compared for 
      treatment effects using inverse probability of treatment weighting. Hazard ratios 
      [95% CI] (HR) for time to next treatment (TTNT) were analyzed using Kaplan-Meier 
      curves. RESULTS: Bendamustine/rituximab was the most common CIT regimen initiated 
      for high-risk patients. During the available follow-up (median 34-35 months), 
      74.7% of the weighted high-risk ibrutinib group received only one line of 
      treatment, compared with 47.2% of the weighted high-risk CIT group. The most 
      common second-line treatment was ibrutinib for those in the CIT groups and 
      venetoclax for the ibrutinib groups. The weighted high-risk ibrutinib group had a 
      significantly longer TTNT (median not reached) than the weighted high-risk CIT 
      group (median 34.4 months) and was 54% less likely to start a new treatment (HR 
      0.5 [0.3-0.6], P < 0.010). Among CIT-treated groups, high-risk patients had 
      significantly shorter median TTNT than non-high-risk patients (P < 0.010). 
      However, within the ibrutinib-treated groups, the median TTNT was similar between 
      high-risk and non-high-risk patients (HR 2.2 [1.0-5.0]; P = 0.060). CONCLUSION: 
      This study found that first-line single-agent ibrutinib therapy was associated 
      with significantly longer TTNT than CIT regimens in real-world patients with 
      high-risk CLL. The results support the use of ibrutinib in high-risk patients. 
      INFOGRAPHIC.
CI  - (c) 2022. The Author(s).
FAU - Huang, Qing
AU  - Huang Q
AD  - Janssen Scientific Affairs, LLC, Horsham, PA, USA.
FAU - Deering, Kathleen L
AU  - Deering KL
AUID- ORCID: 0000-0003-1438-444X
AD  - EPI-Q, Inc., 915 Harger Rd, Suite 350, Oak Brook, IL, USA. 
      katie.deering@epi-q.com.
FAU - Harshaw, Qing
AU  - Harshaw Q
AD  - EPI-Q, Inc., 915 Harger Rd, Suite 350, Oak Brook, IL, USA.
FAU - Leslie, Lori A
AU  - Leslie LA
AD  - John Theurer Cancer Center, Hackensack, NJ, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220524
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - JAC85A2161 (Adenine)
MH  - Adenine/analogs & derivatives
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - Piperidines
MH  - Pyrazoles
MH  - Pyrimidines
MH  - Retrospective Studies
PMC - PMC9239963
OTO - NOTNLM
OT  - Chemoimmunotherapy
OT  - Chronic lymphocytic leukemia
OT  - Cytogenetics
OT  - Ibrutinib
OT  - Real-world evidence
EDAT- 2022/05/25 06:00
MHDA- 2022/07/01 06:00
PMCR- 2022/05/24
CRDT- 2022/05/24 11:20
PHST- 2021/08/03 00:00 [received]
PHST- 2021/11/09 00:00 [accepted]
PHST- 2022/05/25 06:00 [pubmed]
PHST- 2022/07/01 06:00 [medline]
PHST- 2022/05/24 11:20 [entrez]
PHST- 2022/05/24 00:00 [pmc-release]
AID - 10.1007/s12325-021-01991-5 [pii]
AID - 1991 [pii]
AID - 10.1007/s12325-021-01991-5 [doi]
PST - ppublish
SO  - Adv Ther. 2022 Jul;39(7):3292-3307. doi: 10.1007/s12325-021-01991-5. Epub 2022 
      May 24.